Active ingredientNelarabineCat. No. P-N029-001CAS 121032-29-9Family · Pharmaceutical analytical standards
Nelarabine
A purine nucleoside analogue chemotherapy drug, approved in the United States in 2005 for T-cell acute lymphoblastic leukaemia and T-cell lymphoblastic lymphoma that are refractory or have relapsed after at least two chemotherapy regimens. This family brings together the active ingredient and other impurities.
Did you know?It is a water-soluble version of ara-G carrying an extra methoxy group: in the body the enzyme adenosine deaminase removes it, releasing the active drug, to which T lymphocytes are particularly sensitive.
Go to the active ingredient →Active ingredientNelarabineCat. No. P-N029-001CAS 121032-29-9
Impurity2-NitroinosineCat. No. P-N029-002CAS 266360-66-1
ImpurityNelarabine Impurity 1Cat. No. P-N029-003CAS 34793-34-5
ImpurityNelarabine Impurity 2Cat. No. P-N029-004CAS 1233127-29-1
ImpurityNelarabine Impurity 3Cat. No. P-N029-005CAS 7013-16-3
Impurity9-beta-D-ArabinofuranosylguanineCat. No. P-N029-006CAS 38819-10-2
ImpurityAra-DAPCat. No. P-N029-007CAS 34079-68-0
ImpurityNelarabine Impurity 4Cat. No. P-N029-008CAS 1173825-84-7
ImpurityNelarabine Impurity 5 (alpha Isomer)Cat. No. P-N029-009CAS 1305196-84-2
ImpurityO-(6)-MethylguanineCat. No. P-N029-010CAS 20535-83-5No product matches your search.
Need a molecule you cannot find?
Custom synthesis of impurities, metabolites and labelled compounds, with the same characterisation level.